LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held from November 5 – 9, 2015, in Boston, MA.
Curis' collaborator, Aurigene will present data from CA-170 (previously AUPM-170), a first-in-class oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) as well as from the interleukin-1 receptor association kinase4 (IRAK4) inhibitor program. Curis recently exercised options to license both these programs under a collaboration agreement with Aurigene established earlier this year.
Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.
| Poster Presentations | |
| Date/Time: | Friday, Nov. 6, 2015, 12:15 PM – 3:15 PM |
| Session Title: | Immune Modulators |
| Presentation Title: | First-in-class orally available immune checkpoint antagonists for cancer therapy |
| Location: | Session A, Hall C-D |
| Abstract Number: | A96 |
| Date/Time: | Sunday, Nov. 8, 2015, 12:30 PM - 3:30 PM |
| Session Title: | Therapeutic Agents: Small Molecule Kinase Inhibitors |
| Presentation Title: | Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models |
| Location: | Session C, Hall C-D |
| Abstract Number: | C191 |
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, an oral dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exercised options to exclusively license oral small molecule antagonists of PD-L1/ VISTA and IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.